Last update 21 Nov 2024
GEN-1044
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms |
Target |
Mechanism 5T4 modulators(Trophoblast glycoprotein modulators), CD3 modulators(T cell surface glycoprotein CD3 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with GEN-1044First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1044 in Subjects With Malignant Solid Tumors
First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1044 in subjects with malignant solid tumors
100 Clinical Results associated with GEN-1044
Login to view more data
100 Translational Medicine associated with GEN-1044
Login to view more data
100 Patents (Medical) associated with GEN-1044
Login to view more data
1
Literatures (Medical) associated with GEN-104401 Nov 2022Life Science Alliance
Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models
Article
Author: Janmaat, Maarten L ; Rademaker, Rik ; Satijn, David ; Burm, Saskia M ; Gielen, Ellis ; Verzijl, Dennis ; Kemper, Kristel ; van den Brink, Edward N ; Sasser, A Kate ; Koopman, Louise A ; de Poot, Stefanie AH ; Plantinga, Theo S ; Houtkamp, Mischa ; Boross, Peter ; Engelberts, Patrick J ; Breij, Esther CW
100 Deals associated with GEN-1044
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Metastatic Solid Tumor | Phase 2 | DK | 15 Jul 2020 | |
| Neoplasms | Phase 2 | - | - | |
| Prostatic Cancer | Preclinical | US | 15 Jul 2020 | |
| Prostatic Cancer | Preclinical | ES | 15 Jul 2020 | |
| Prostatic Cancer | Preclinical | DK | 15 Jul 2020 | |
| Esophageal Carcinoma | Discovery | US | 15 Jul 2020 | |
| Esophageal Carcinoma | Discovery | IL | 15 Jul 2020 | |
| Esophageal Carcinoma | Discovery | ES | 15 Jul 2020 | |
| Esophageal Carcinoma | Discovery | DK | 15 Jul 2020 | |
| Prostatic Cancer | Discovery | IL | 15 Jul 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | 48 | (GEN1044 Doses 0.3/3/3 mg) | rppujuvplw(dehkinpgsz) = agzddzhckd riqvarghqe (cabffiqhtz, qertjjakwc - tlwirgdjbd) View more | - | 01 Feb 2023 | ||
(GEN1044 Doses 1/3/10 mg) | rppujuvplw(dehkinpgsz) = rsdfbttbqy riqvarghqe (cabffiqhtz, hksvwswddf - nynzkvezym) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free